The first article of my blog series on Yaz, Yasmin, Ocella, Gianvi, Safyral, and Beyaz discussed how Yaz in particular was marketed to treat premenstrual dysphoric disorder (PMDD)--before PMDD was even classified as a medical condition--so that the drug manufacturer, Bayer, could increase their profits. In this article, I will provide … [Read more...]
Asbestos ban to be announced by federal government next week
The federal government plans to announce a comprehensive ban on asbestos in Canada next week, CBC News has learned. The country currently allows imports of construction products and automotive parts that contain the toxic fibre, even though Canada no longer exports the material. Asbestos is known to cause deadly cancers and lung diseases, and … [Read more...]
Long-Term Use Of Prevacid, Prilosec, and Nexium May Lead To Strokes
In November 2016 we learned about a new study that suggests these popular category heartburn medications, known as proton pump inhibitors (PPIs), may increase the risk of ischemic strokes. From a press release from the American Heart Association, “Popular heartburn medication may increase ischemic stroke risk”, we get the following facts: A … [Read more...]
Canada should stop importing deadly asbestos, labour group says
The Canadian Labour Congress is calling for a ban on asbestos. Exposure to asbestos — a fibrous mineral used in building and construction — is the leading cause of workplace-related death in Canada. Canada stopped exporting asbestos in 2011, and its last asbestos mine closed in 2012. But Canada still imports asbestos for use in construction … [Read more...]
Treatments to prolong life for mesothelioma patients closer
Researchers have uncovered a strange way that asbestos-related tumours grow, which could pave the way towards better treatments. The scientists at Adelaide’s Flinders University have found that malignant mesothelioma tumours are able to transform into blood vessels, promoting their own growth. Associate Professor Sonja Klebe said the behaviour … [Read more...]
Birth Control Pills Series: Creating a Clinical Disorder for Profit
To start my blog series on Yaz, Yasmin, Ocella, Gianvi, Safyral, and Beyaz, I will focus on Yaz in particular, and one of the conditions that it is prescribed to treat. Though drugs are generally created for the purpose of treating existing medical conditions, this is not always the case. In fact, corruption in the system can sometimes … [Read more...]
Manufacturers of Depakote Face Lawsuits at Home and Abroad
Recently, the drug manufacturers of Depakote (valproate) and its derivatives have come under legal fire for failing to warn about the possible side effects of the drug, and blatantly concealing warnings in order to increase their profits. In the United States, AbbVie Inc. (formerly Abbott Laboratories) manufactures Depakote, Depakine, and … [Read more...]
New Paradigms in the Treatment of Mesothelioma and NSCLC: An Overview by Fred Hirsch
Dr. Haffizulla: Welcome to PracticeUpdate. I’m Dr. Farzanna Haffizulla. Joining me today is Dr. Fred Hirsch, CEO of the International Association for the Study of Lung Cancer, and Professor of Medicine at the University of Colorado in Denver. Dr. Hirsch, thank you, so much, for joining me. Dr. Hirsch: Thank you, so much, for the invitation. Dr. … [Read more...]
Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma
Malignant pleural mesothelioma shows marked cytoarchitectural diversity. The aim of the study was to evaluate how morphological phenotype impacted upon overall survival. 191 cases of malignant pleural mesothelioma with available follow-up were identified, examined and classified according to histological types. The epithelioid mesotheliomas were … [Read more...]
Defendants BMS And Pfizer Ask For Eliquis Federal Court Consolidation
On October 13, 2016 attorneys for Bristol-Myers Squibb Company and Pfizer Inc. filed with the United States Judicial Panel on Multidistrict Litigation (JPML) this court document, “BRISTOL-MYERS SQUIBB COMPANY AND PFIZER INC.’S MOTION FOR TRANSFER OF RELATED ELIQUIS (APIXABAN) PRODUCTS LIABILITY ACTIONS FOR COORDINATED PRETRIAL PROCEEDINGS PURSUANT … [Read more...]
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 50
- Next Page »